Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Efficacy of zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

Mazyar Shadman • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia General Leukemia Acalabrutinib Ibrutinib Zanubrutinib

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the efficacy of zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Mazyar Shadman

Expanding the CAR platform for NHL 11:30
Expanding the CAR platform for NHL
Catherine Bollard et al. • 28 Sep 2025
The role of zanubrutinib in CLL treatment and its relative efficacy compared to other BTKis 2:10
The role of zanubrutinib in CLL treatment and its relative efficacy compared to other BTKis
Mazyar Shadman • 13 Sep 2025
The development of resource-restricted guidelines for the diagnosis and management of CLL 4:43
The development of resource-restricted guidelines for the diagnosis and management of CLL
Mazyar Shadman • 13 Sep 2025
Rare symptoms and complications in CLL 1:22
Rare symptoms and complications in CLL
Mazyar Shadman • 13 Sep 2025

Related Videos

HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML 8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
POD36 as a prognostic marker and clinical tool in frontline CLL 3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology 7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
Recent advancements in the understanding of Richter’s transformation 1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals